Skeletal Complications of Breast Cancer Therapies

Nonsurgical treatment options, such as hormonal therapy, chemotherapy, radiation, and bisphosphonate therapy, are undoubtedly improving outcomes for women with breast cancer; however, these therapies also carry significant skeletal side effects. For example, adjuvant hormonal treatments, such as aro...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 12; no. 20; pp. 6309s - 6314s
Main Authors HIRBE, Angela, MORGAN, Elizabeth A, ULUCKAN, Özge, WEILBAECHER, Katherine
Format Journal Article Conference Proceeding
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.10.2006
Subjects
Antineoplastic agents
Antineoplastic Agents - adverse effects
aromatase inhibitors
Biological and medical sciences
bisphosphonates
Bone Diseases - etiology
bone mineral loss
Breast Neoplasms - therapy
Clinical Trials as Topic
estrogen
Female
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Pharmacology. Drug treatments
Radiotherapy - adverse effects
Tumors
Mammary gland diseases
Complication
Skeleton
Breast cancer
Treatment
Malignant tumor
Online AccessGet full text

Cover

More Information
Summary:Nonsurgical treatment options, such as hormonal therapy, chemotherapy, radiation, and bisphosphonate therapy, are undoubtedly improving outcomes for women with breast cancer; however, these therapies also carry significant skeletal side effects. For example, adjuvant hormonal treatments, such as aromatase inhibitors that disrupt the estrogen-skeleton axis, have the potential to cause decreased bone mineral density. Similarly, chemotherapy often induces primary ovarian failure in premenopausal women, resulting in decreased levels of circulating estrogen and subsequent osteopenia. In both cases, women receiving these therapies are at an increased risk for the development of osteoporosis and skeletal fracture. Furthermore, women undergoing radiation therapy to the upper body may have an increased incidence of rib fracture, and those receiving bisphosphonates may be vulnerable to the development of osteonecrosis of the jaw. Therefore, women with breast cancer who are undergoing any of these therapies should be closely monitored for bone mineral loss and advised of skeletal health maintenance strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-06-0652